Mihael Hristos Polymeropoulos
Known title: President and CEOCIK: 0001355537
Mihael Hristos Polymeropoulos's purchase track record
How the stock did after each of Mihael Hristos Polymeropoulos's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since February 25, 2025
Stock higher 6 months later
75%
3 months: 50%
Median 6-month return
+4.6%
3 months: +0.9%
Beat the S&P 500
25%
median -6.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/7/2025 | VNDA | $42K | +5.0% | +72.1% | +7.2% |
| 5/16/2025 | VNDA | $128K | +4.8% | +4.6% | +13.0% |
| 3/5/2025 | VNDA | $100K | -13.5% | -8.0% | +10.4% |
| 2/25/2025 | VNDA | $235K | -2.9% | +4.7% | +8.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VNDA | ▼ Sell | Open Market | 156,235 | $1.3M | 3/2/2026 | View on chart |
| VNDA | ▲ Buy | Grant | 525,000 | $0 | 2/18/2026 | View on chart |
| VNDA | ▲ Buy | Open Market | 10,000 | $42K | 8/7/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 9,519 | $42K | 5/21/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 481 | $2K | 5/21/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 20,000 | $84K | 5/16/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 5,000 | $25K | 3/6/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 5,000 | $25K | 3/6/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 5,000 | $25K | 3/5/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 5,000 | $25K | 3/5/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 10,000 | $47K | 3/3/2025 | View on chart |
| VNDA | ▼ Sell | Tax Withholding | 95,999 | $457K | 3/1/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 10,000 | $48K | 2/28/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 10,000 | $48K | 2/27/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 5,000 | $24K | 2/26/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 5,000 | $24K | 2/26/2025 | View on chart |
| VNDA | ▲ Buy | Open Market | 10,000 | $45K | 2/25/2025 | View on chart |
| VNDA | ▲ Buy | Grant | 450,000 | $0 | 2/18/2025 | View on chart |
| VNDA | ▼ Sell | Open Market | 24,288 | $100K | 3/5/2024 | View on chart |
| VNDA | ▼ Sell | Open Market | 30,884 | $131K | 3/4/2024 | View on chart |
| VNDA | ▲ Buy | Grant | 450,000 | $0 | 2/16/2024 | View on chart |
| VNDA | ▼ Sell | Open Market | 22,538 | $141K | 3/3/2023 | View on chart |
| VNDA | ▼ Sell | Open Market | 22,426 | $140K | 3/2/2023 | View on chart |
| VNDA | ▲ Buy | Grant | 115,000 | $0 | 2/16/2023 | View on chart |
| VNDA | ▲ Buy | Option Exercise | 75,365 | $235K | 12/6/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 48,250 | $512K | 12/6/2022 | View on chart |
| VNDA | ▲ Buy | Option Exercise | 74,635 | $233K | 12/5/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 47,650 | $506K | 12/5/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 29,588 | $330K | 3/2/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 7,508 | $84K | 3/1/2022 | View on chart |
| VNDA | ▲ Buy | Grant | 115,000 | $0 | 2/28/2022 | View on chart |
| VNDA | ▲ Buy | Option Exercise | 71,676 | $350K | 12/1/2021 | View on chart |
| VNDA | ▼ Sell | Open Market | 46,200 | $739K | 12/1/2021 | View on chart |
| VNDA | ▲ Buy | Option Exercise | 78,324 | $382K | 11/30/2021 | View on chart |
| VNDA | ▼ Sell | Open Market | 50,000 | $824K | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.